Literature DB >> 22160002

Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Sebastian Michael1, Heba Abdel-Aziz, Dieter Weiser, Christa E Müller, Olaf Kelber, Karen Nieber.   

Abstract

STW 5 (Iberogast®), an established herbal combination, was effective in randomized, double blind clinical studies in functional dyspepsia and irritable bowel syndrome. Since STW 5 was found to influence intestinal motility and has anti-inflammatory properties, this study investigated the expression of adenosine receptors and characterized their role in the control of the anti-inflammatory action of STW 5 and its fresh plant component STW 6 in inflammation-disturbed rat small intestinal preparations. The inflammation was induced by intraluminal instillation of 2,4,6-trinitrobenzene sulfonic acid (TNBS, 0.01 M). The effects of coincubation with selective receptor agonists and antagonists, STW 5, STW 6, or combinations of these compounds on acetylcholine (ACh)-evoked contraction of ileum/jejunum preparations were tested. Adenosine receptor mRNA expression was examined by reverse transcription-polymerase chain reaction (RT-PCR). In untreated preparations, RT-PCR revealed the presence of all adenosine receptor subtypes. Suppressed expression was detected for all subtypes in inflamed tissues, except for A(2B)R mRNA, which was unaffected. STW 5 reversed these effects and enhanced A(2A)R expression above control levels. Radioligand binding assays confirm the affinity of STW 5 to the A(2A)R, and the A(2A)R antagonist was able to prevent the effect of STW 5 on TNBS-induced attenuation of the ACh contraction. Our findings provide evidence that STW 5, but not STW 6 interacts with A(2A)R, which is involved in the anti-inflammatory action of STW 5. STW 6 did not contribute to adenosine A(2A)R-mediated anti-inflammatory effect of STW 5. Other signaling pathways could be involved in the mechanism of action of STW 6.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160002     DOI: 10.1007/s00210-011-0714-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  67 in total

Review 1.  Adenosine A2A receptor agonists as anti-inflammatory agents.

Authors:  Gail W Sullivan
Journal:  Curr Opin Investig Drugs       Date:  2003-11

Review 2.  Enteric neuroimmunophysiology and pathophysiology.

Authors:  Jackie D Wood
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

3.  Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

Authors:  A Madisch; G Holtmann; K Plein; J Hotz
Journal:  Aliment Pharmacol Ther       Date:  2004-02-01       Impact factor: 8.171

4.  A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis.

Authors:  Luca Antonioli; Matteo Fornai; Rocchina Colucci; Narcisa Ghisu; Corrado Blandizzi; Mario Del Tacca
Journal:  Inflamm Bowel Dis       Date:  2006-02       Impact factor: 5.325

5.  Adenosine A(2A) agonist and A(2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation.

Authors:  Sebastian Michael; Claudia Warstat; Fabien Michel; Luo Yan; Christa E Müller; Karen Nieber
Journal:  Purinergic Signal       Date:  2009-12-18       Impact factor: 3.765

6.  2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors.

Authors:  K N Klotz; M J Lohse; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

Review 7.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  HIF-dependent induction of adenosine A2B receptor in hypoxia.

Authors:  Tianqing Kong; Karen A Westerman; Marion Faigle; Holger K Eltzschig; Sean P Colgan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

9.  Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.

Authors:  Christa E Müller; Mark Thorand; Ramatullah Qurishi; Martina Diekmann; Kenneth A Jacobson; William L Padgett; John W Daly
Journal:  J Med Chem       Date:  2002-08-01       Impact factor: 7.446

10.  Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia.

Authors:  Andras Bilkei-Gorzo; Osama M Abo-Salem; Alaa M Hayallah; Kerstin Michel; Christa E Müller; Andreas Zimmer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-10       Impact factor: 3.000

View more
  5 in total

Review 1.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 2.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

3.  Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells.

Authors:  Mathias Schneider; Thomas Efferth; Heba Abdel-Aziz
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

4.  Phytotherapy of chronic abdominal pain following pancreatic carcinoma surgery: a single case observation.

Authors:  Karl Rüdiger Wiebelitz; André-Michael Beer
Journal:  Int J Gen Med       Date:  2012-10-16

Review 5.  Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast.

Authors:  Heba Abdel-Aziz; Olaf Kelber; Gerhard Lorkowski; Martin Storr
Journal:  Planta Med       Date:  2017-08-31       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.